Health Care [ 7/12 ] | Pharmaceuticals [ 40/74 ]
NYSE | Common Stock
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
The company also focuses on the central nervous system (CNS), respiratory, and oncology areas.
It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.
The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder.
The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names.
It has collaboration agreements with MedinCellS. A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH.
The company was founded in 1901 and is based in Tel Aviv, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jan 29, 25 | 0.71 Decreased by -29.00% | 0.70 Increased by +1.08% |
| Nov 6, 24 | 0.69 Increased by +15.00% | 0.65 Increased by +6.15% |
| Jul 31, 24 | 0.61 Increased by +8.93% | 0.55 Increased by +10.91% |
| May 8, 24 | 0.48 Increased by +20.00% | 0.51 Decreased by -5.88% |
| Jan 31, 24 | 1.00 Increased by +40.85% | 0.77 Increased by +29.87% |
| Nov 8, 23 | 0.60 Increased by +1.69% | 0.61 Decreased by -1.64% |
| Aug 2, 23 | 0.56 Decreased by -17.65% | 0.53 Increased by +5.66% |
| May 10, 23 | 0.40 Decreased by -27.27% | 0.56 Decreased by -28.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 4.23 B Decreased by -5.12% | -217.00 M Decreased by -150.58% | Decreased by -5.13% Decreased by -153.31% |
| Sep 30, 24 | 4.33 B Increased by +12.52% | -437.00 M Decreased by -646.25% | Decreased by -10.09% Decreased by -585.47% |
| Jun 30, 24 | 4.16 B Increased by +7.32% | -845.00 M Increased by +2.09% | Decreased by -20.30% Increased by +8.77% |
| Mar 31, 24 | 3.83 B Increased by +4.67% | -139.00 M Increased by +32.20% | Decreased by -3.63% Increased by +35.22% |
| Dec 31, 23 | 4.46 B Increased by +14.75% | 429.00 M Increased by +135.14% | Increased by +9.63% Increased by +130.62% |
| Sep 30, 23 | 3.85 B Increased by +7.09% | 80.00 M Increased by +42.86% | Increased by +2.08% Increased by +33.40% |
| Jun 30, 23 | 3.88 B Increased by +2.46% | -863.00 M Decreased by -271.98% | Decreased by -22.25% Decreased by -263.06% |
| Mar 31, 23 | 3.66 B Increased by 0.00% | -205.00 M Increased by +78.53% | Decreased by -5.60% Increased by +78.53% |